20, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered ... and autologous vein graft is not feasible. Vascular trauma occurs when ...

Based on the model, the per-patient cost of treating patients with Symvess is estimated to be less than the cost of treating trauma patients with synthetic grafts, cryopreserved allografts ...

Dec. 20, 2024 /PRNewswire/ -- The U.S. Food and Drug Administration approved Symvess, the first acellular tissue engineered vessel indicated for use in adults as a vascular conduit for extremity ...